Laboratory test responses to dDAVP before and during treatment with tolvaptan
| . | Screening . | Before tolvaptan . | During tolvaptan . | ||
|---|---|---|---|---|---|
| Before dDAVP . | After dDAVP . | Before dDAVP . | After dDAVP . | ||
| VWF antigen, % (50%-150%) | 43 | 57 | 116 | 51 | 47 |
| PFA-100 collagen/epinephrine, s (74-186 s) | 225 | 245 | 111 | 244 | 211 |
| PFA-100 collagen/ADP, s (56-128 s) | 148 | 160 | 93 | 158 | 150 |
| VWF ristocetin cofactor activity, % (50%-125%) | 40 | 46 | 131 | 53 | 51 |
| Factor VIII coagulant activity, % (56%-172%) | 53 | 52 | 120 | 57 | 56 |
| Activated PTT, s (25-35 s) | 33.7 | 35.5 | 29.4 | 35.0 | 34.3 |
| VWF multimer | Normal | Normal | Larger than normal | Normal | Normal |
| Factor XI coagulant activity, % (69%-155%) | 89 | ||||
| Factor IX coagulant activity, % (69%-176%) | 79 | ||||
| Prothrombin time INR | 1.0 | ||||
| WBC, ×103/μL | 3.9 | ||||
| Hemoglobin, g/dL | 13.6 | ||||
| Platelet count, ×103/μL | 121 | ||||
| Serum LDH, IU/L | 172 | ||||
| BUN, mg/dL | 23 | ||||
| Serum creatinine, mg/dL | 1.3 | ||||
| eGFR, mL/min/1.73 m2 | 64.3 | ||||
| MRI results | |||||
| Left kidney length, cm | 21.3 | ||||
| Right kidney length, cm | 20.2 | ||||
| Total kidney volume, mL | 1960 | ||||
| Liver length, cm | 22 | ||||
| Spleen length, cm | 13.6 | ||||
| . | Screening . | Before tolvaptan . | During tolvaptan . | ||
|---|---|---|---|---|---|
| Before dDAVP . | After dDAVP . | Before dDAVP . | After dDAVP . | ||
| VWF antigen, % (50%-150%) | 43 | 57 | 116 | 51 | 47 |
| PFA-100 collagen/epinephrine, s (74-186 s) | 225 | 245 | 111 | 244 | 211 |
| PFA-100 collagen/ADP, s (56-128 s) | 148 | 160 | 93 | 158 | 150 |
| VWF ristocetin cofactor activity, % (50%-125%) | 40 | 46 | 131 | 53 | 51 |
| Factor VIII coagulant activity, % (56%-172%) | 53 | 52 | 120 | 57 | 56 |
| Activated PTT, s (25-35 s) | 33.7 | 35.5 | 29.4 | 35.0 | 34.3 |
| VWF multimer | Normal | Normal | Larger than normal | Normal | Normal |
| Factor XI coagulant activity, % (69%-155%) | 89 | ||||
| Factor IX coagulant activity, % (69%-176%) | 79 | ||||
| Prothrombin time INR | 1.0 | ||||
| WBC, ×103/μL | 3.9 | ||||
| Hemoglobin, g/dL | 13.6 | ||||
| Platelet count, ×103/μL | 121 | ||||
| Serum LDH, IU/L | 172 | ||||
| BUN, mg/dL | 23 | ||||
| Serum creatinine, mg/dL | 1.3 | ||||
| eGFR, mL/min/1.73 m2 | 64.3 | ||||
| MRI results | |||||
| Left kidney length, cm | 21.3 | ||||
| Right kidney length, cm | 20.2 | ||||
| Total kidney volume, mL | 1960 | ||||
| Liver length, cm | 22 | ||||
| Spleen length, cm | 13.6 | ||||
dDAVP dose (0.3 μg/kg): blood samples obtained 30 minutes after dDAVP infusion. “During tolvaptan” blood samples obtained 2 hours after the morning dose of tolvaptan.
VWF indicates von Willebrand factor; PFA, platelet function analyzer; INR, international normalized ratio; WBC, white blood cell count; LDH, lactate dehydrogenase; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate by Modification of Diet in Renal Disease formula; and MRI, magnetic resonance imaging.